Laboratorios Farmacéuticos Rovi, S.A.

small molecule and specialty biologics; injectable/prefilled-syringe CDMO

ROVI · BME · Spain

Public Market Listing

ROVIBME

BME primary exchange listing

Live quotes, historical charts, and market capitalization for Laboratorios Farmacéuticos Rovi, S.A. are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1
Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule
Schizophrenia

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

3 September 2025WithdrawalRisperidone (Risvan)FDA withdraws approval of NDA 214835 (Federal Register 2025-14683)
US, FDA · Source ↗

Financial reports

No financial reports recorded.